

AMENDMENTS TO THE SPECIFICATION

Page 1, line 18, replace the paragraph setting forth the priority claim:

This is a continuation of U.S. application serial no. 08/475,813, filed June 7, 1995, now U.S. Patent No. 6,682,734; which is a divisional of U.S. application serial no. 08/149,099, filed November 3, 1993, now U.S. Patent No. 5,736,137; which is a continuation-in-part of U.S. application serial no. 07/978,891, filed November 13, 1992, now abandoned. This patent document is related to U.S. application serial no. 07/977,691, filed November 13, 1992, now abandoned [I,] ; and U.S. application serial no. 08/147,696, filed November 3, 1993, now U.S. Patent No. 5,648,267, both entitled "IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND EXPRESSION VECTOR SYSTEMS COMPRISING SAME." Related patent applications 07/978,891, 07/977,691, and 08/147,696 are incorporated herein by reference.

Page 20, line 7, replace the last full paragraph on the page:

Another approach, and one which is our most preferred approach for developing a chimeric non-human/human anti-CD20 antibody, is based upon utilization of an expression vector which includes, *ab initio*, DNA encoding heavy and light chain constant regions from a human source. Such a vector allows for inserting DNA encoding non-human variable regions such that a variety of non-human anti-CD20 antibodies can be generated, screened and analyzed for various characteristics (*eg* type of binding specificity, epitope binding regions, etc.); thereafter, cDNA encoding the light and heavy chain variable regions from a preferred or desired anti-CD20 antibody can be incorporated into the vector. We refer to these types of vectors as Tandem Chimeric Antibody Expression ("TCAE") vectors. A most preferred TCAE vector which was used to generate immunologically active chimeric anti-CD20 antibodies for therapeutic treatment of lymphomas is TCAE 8. TCAE 8 is a derivative of a vector owned by the assignee of this

patent document, referred to as TCAE 5.2, the difference being that in TCAE 5.2, the translation initiation start site of the dominant selectable marker (neomycin phosphotransferase, "NEO") is a consensus Kozak sequence, while for TCAE 8, this region is a partially impaired consensus Kozak sequence. Details regarding the impact of the initiation start site of the dominant selectable marker of the TCAE vectors (also referred to as "ANEX vector") vis-a-vis protein expression are disclosed in detail in ~~the~~ co-pending application serial no. 08/147,696, now U.S. Patent No. 5,648,267, filed herewith.

Replace the abstract with the amended abstract shown on the following page.

Replace the sequence listing with the substitute sequence listing appended to this reply.